References

1. WHO. Leishmaniasis. Available online: (accessed on 15 February 2021).
2. Bates, P.A. The developmental biology of Leishmania promastigotes. Exp. Parasitol. 1994, 79, 215–218.
3. Sacks, D.L.; Perkins, P.V. Identification of an infective stage of Leishmania promastigotes. Science 1984, 223, 1417–1419.
4. Merritt, C.; Silva, L.E.; Tanner, A.L.; Stuart, K.; Pollastri, M.P. Kinases as druggable targets in trypanosomatid protozoan parasites. Chem. Rev. 2014, 114, 11280–11304.
5. Burza, S.; Croft, S.L.; Boelaert, M. Leishmaniasis. Lancet 2018, 392, 951–970.
6. Colmenares, M.; Kar, S.; Goldsmith-Pestana, K.; McMahon-Pratt, D. Mechanisms of pathogenesis: Differences amongst Leishmania species. Trans. R Soc. Trop. Med. Hyg. 2002, 96 (Suppl. 1), S3–S7.
7. Zijlstra, E.E. PKDL and other dermal lesions in HIV co-infected patients with Leishmaniasis: Review of clinical presentation in relation to immune responses. PLoS Negl. Trop. Dis. 2014, 8, e3258.
8. Cincurá, C.; de Lima, C.M.F.; Machado, P.R.L.; Oliveira-Filho, J.; Glesby, M.J.; Lessa, M.M.; Carvalho, E.M. Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of Leishmania (Viannia) braziliensis. Am. J. Trop. Med. Hyg. 2017, 97, 761–766.
9. Maltezou, H.C. Drug resistance in visceral leishmaniasis. J. Biomed. Biotechnol. 2010, 2010, 617521.
10. Uliana, S.R.B.; Trinconi, C.T.; Coelho, A.C. Chemotherapy of leishmaniasis: Present challenges. Parasitology 2018, 145, 464–480.
11. Hailu, A.; Musa, A.; Wasunna, M.; Balasegaram, M.; Yifru, S.; Mengistu, G.; Hurissa, Z.; Hailu, W.; Weldegebreal, T.; Tesfaye, S.; et al. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: A multicentre, open-label, randomized trial. PLoS Negl. Trop. Dis. 2010, 4, e709.
12. Musa, A.; Khalil, E.; Hailu, A.; Olobo, J.; Balasegaram, M.; Omollo, R.; Edwards, T.; Rashid, J.; Mbui, J.; Musa, B.; et al. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: A randomised controlled trial. PLoS Negl. Trop. Dis. 2012, 6, e1674.
13. Jha, S.N.; Singh, N.K.; Jha, T.K. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J. Assoc. Physicians India 1991, 39, 314–316.
14. Rahman, M.; Ahmed, B.N.; Faiz, M.A.; Chowdhury, M.Z.; Islam, Q.T.; Sayeedur, R.; Rahman, M.R.; Hossain, M.; Bangali, A.M.; Ahmad, Z.; et al. Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh. Am. J. Trop. Med. Hyg. 2011, 85, 66–69.
15. Bhattacharya, S.K.; Sinha, P.K.; Sundar, S.; Thakur, C.P.; Jha, T.K.; Pandey, K.; Das, V.R.; Kumar, N.; Lal, C.; Verma, N.; et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J. Infect. Dis. 2007, 196, 591–598.
16. Dorlo, T.P.; van Thiel, P.P.; Huitema, A.D.; Keizer, R.J.; de Vries, H.J.; Beijnen, J.H.; de Vries, P.J. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob. Agents Chemother. 2008, 52, 2855–2860.
17. Bahrami, S.; Oryan, A.; Bemani, E. Efficacy of amiodarone and voriconazole combination therapy in cutaneous leishmaniasis in the mice experimentally infected with Leishmania major. J. Infect. Chemother. 2021.
18. Andrade-Neto, V.V.; Rebello, K.M.; Pereira, T.M.; Torres-Santos, E.C. Effect of Itraconazole-Ezetimibe-Miltefosine Ternary Therapy in Murine Visceral Leishmaniasis. Antimicrob. Agents Chemother. 2021.
19. Ahmed, H.; Curtis, C.R.; Tur-Gracia, S.; Olatunji, T.O.; Carter, K.C.; Williams, R.A.M. Drug combinations as effective anti-leishmanials against drug resistant. RSC Med. Chem. 2020, 11, 905–912.
20. Gugliandolo, E.; Palma, E.; Peritore, A.F.; Siracusa, R.; D’Amico, R.; Fusco, R.; Licata, P.; Crupi, R. Effect of Artesunate on Leishmania Amazonesis Induced Neuroinflammation and Nociceptive Behavior in Male Balb/C Mice. Animals 2020, 10, 557.
21. Medkour, H.; Bitam, I.; Laidoudi, Y.; Lafri, I.; Lounas, A.; Hamidat, H.K.; Mekroud, A.; Varloud, M.; Davoust, B.; Mediannikov, O. Potential of Artesunate in the treatment of visceral leishmaniasis in dogs naturally infected by Leishmania infantum: Efficacy evidence from a randomized field trial. PLoS Negl. Trop. Dis. 2020, 14, e0008947.
22. Machín, L.; Nápoles, R.; Gille, L.; Monzote, L. Leishmania amazonensis response to artemisinin and derivatives. Parasitol. Int. 2021, 80, 102218.
23. Mutiso, J.M.; Macharia, J.C.; Barasa, M.; Taracha, E.; Bourdichon, A.J.; Gicheru, M.M. In vitro and in vivo antileishmanial efficacy of a combination therapy of diminazene and artesunate against Leishmania donovani in BALB/c mice. Rev. Inst. Med. Trop. Sao Paulo 2011, 53, 129–132.
24. Meijer, L.; Skaltsounis, A.L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X.P.; Vonica, C.A.; Brivanlou, A.; Dajani, R.; et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol. 2003, 10, 1255–1266.
25. Grant, K.M.; Dunion, M.H.; Yardley, V.; Skaltsounis, A.L.; Marko, D.; Eisenbrand, G.; Croft, S.L.; Meijer, L.; Mottram, J.C. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: Chemical library screen and antileishmanial activity. Antimicrob. Agents Chemother. 2004, 48, 3033–3042.
26. Xingi, E.; Smirlis, D.; Myrianthopoulos, V.; Magiatis, P.; Grant, K.M.; Meijer, L.; Mikros, E.; Skaltsounis, A.L.; Soteriadou, K. 6-Br-5methylindirubin-3′oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: Exploitation of GSK-3 for treating leishmaniasis. Int. J. Parasitol. 2009, 39, 1289–1303.
27. Efstathiou, A.; Gaboriaud-Kolar, N.; Smirlis, D.; Myrianthopoulos, V.; Vougogiannopoulou, K.; Alexandratos, A.; Kritsanida, M.; Mikros, E.; Soteriadou, K.; Skaltsounis, A.L. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3. Parasit. Vectors 2014, 7, 234.
28. Efstathiou, A.; Meira, C.S.; Gaboriaud-Kolar, N.; Bastos, T.M.; Rocha, V.P.C.; Vougogiannopoulou, K.; Skaltsounis, A.L.; Smirlis, D.; Soares, M.B.P. Indirubin derivatives are potent and selective anti-Trypanosoma cruzi agents. Virulence 2018, 9, 1658–1668.
29. Efstathiou, A.; Gaboriaud-Kolar, N.; Myrianthopoulos, V.; Vougogiannopoulou, K.; Subota, I.; Aicher, S.; Mikros, E.; Bastin, P.; Skaltsounis, A.L.; Soteriadou, K.; et al. Indirubin Analogues Inhibit Trypanosoma brucei Glycogen Synthase Kinase-3 Short and T. brucei Growth. Antimicrob. Agents Chemother. 2019, 63.
30. Karampetsou, K.; Koutsoni, O.S.; Gogou, G.; Angelis, A.; Skaltsounis, L.A.; Dotsika, E. Total Phenolic Fraction (TPF) from Extra Virgin Olive Oil: Induction of apoptotic-like cell death in Leishmania spp. promastigotes and in vivo potential of therapeutic immunomodulation. PLoS Negl. Trop. Dis. 2021, 15, e0008968.
31. Timmers, L.F.; Pauli, I.; Barcellos, G.B.; Rocha, K.B.; Caceres, R.A.; de Azevedo, W.F.; Soares, M.B. Genomic databases and the search of protein targets for protozoan parasites. Curr. Drug Targets 2009, 10, 240–245.
32. Ivens, A.C.; Peacock, C.S.; Worthey, E.A.; Murphy, L.; Aggarwal, G.; Berriman, M.; Sisk, E.; Rajandream, M.A.; Adlem, E.; Aert, R.; et al. The genome of the kinetoplastid parasite, Leishmania major. Science 2005, 309, 436–442.
33. Smirlis, D.; Soares, M.B. Selection of molecular targets for drug development against trypanosomatids. Subcell. Biochem. 2014, 74, 43–76.
34. Wu, P.; Nielsen, T.E.; Clausen, M.H. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol. Sci. 2015, 36, 422–439.
35. Parsons, M.; Worthey, E.A.; Ward, P.N.; Mottram, J.C. Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 2005, 6, 127.
36. Borba, J.V.B.; Silva, A.C.; Ramos, P.I.P.; Grazzia, N.; Miguel, D.C.; Muratov, E.N.; Furnham, N.; Andrade, C.H. Unveiling the Kinomes of Leishmania infantum and L. braziliensis Empowers the Discovery of New Kinase Targets and Antileishmanial Compounds. Comput. Struct. Biotechnol. J. 2019, 17, 352–361.
37. Baker, N.; Catta-Preta, C.M.C.; Neish, R.; Sadlova, J.; Powell, B.; Alves-Ferreira, E.V.C.; Geoghegan, V.; Carnielli, J.B.T.; Newling, K.; Hughes, C.; et al. Systematic functional analysis of Leishmania protein kinases identifies regulators of differentiation or survival. Nat. Commun. 2021, 12, 1244.
38. Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298, 1912–1934.
39. Hanks, S.K.; Hunter, T. Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification. FASEB J. 1995, 9, 576–596.
40. Knighton, D.R.; Zheng, J.H.; Ten Eyck, L.F.; Ashford, V.A.; Xuong, N.H.; Taylor, S.S.; Sowadski, J.M. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991, 253, 407–414.
41. Hubbard, S.R.; Wei, L.; Ellis, L.; Hendrickson, W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994, 372, 746–754.
42. Brinkworth, R.I.; Breinl, R.A.; Kobe, B. Structural basis and prediction of substrate specificity in protein serine/threonine kinases. Proc. Natl. Acad. Sci. USA 2003, 100, 74–79.
43. Nolen, B.; Taylor, S.; Ghosh, G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol. Cell 2004, 15, 661–675.
44. Taylor, S.S.; Knighton, D.R.; Zheng, J.; Ten Eyck, L.F.; Sowadski, J.M. Structural framework for the protein kinase family. Annu. Rev. Cell Biol. 1992, 8, 429–462.
45. Kobe, B.; Kemp, B.E. Principles of Kinase Regulation. In Handbook of Cell Signaling, 2/e; Elsevier Inc.: Cambridge, MA, USA, 2010; pp. 559–563.
46. Böhmer, F.D.; Karagyozov, L.; Uecker, A.; Serve, H.; Botzki, A.; Mahboobi, S.; Dove, S. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. 2003, 278, 5148–5155.
47. Morgan, D.O. Cell cycle: Principles of control. Yale J. Biol. Med. 2007, 80, 141–142.
48. Lohka, M.J.; Hayes, M.K.; Maller, J.L. Purification of maturation-promoting factor, an intracellular regulator of early mitotic events. Proc. Natl. Acad. Sci. USA 1988, 85, 3009–3013.
49. Nurse, P. Universal control mechanism regulating onset of M-phase. Nature 1990, 344, 503–508.
50. Dulić, V.; Lees, E.; Reed, S.I. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 1992, 257, 1958–1961.
51. Sherr, C.J. G1 phase progression: Cycling on cue. Cell 1994, 79, 551–555.
52. Rosenblatt, J.; Gu, Y.; Morgan, D.O. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc. Natl. Acad. Sci. USA 1992, 89, 2824–2828.
53. Deshpande, A.; Sicinski, P.; Hinds, P.W. Cyclins and cdks in development and cancer: A perspective. Oncogene 2005, 24, 2909–2915.
54. Hassan, P.; Fergusson, D.; Grant, K.M.; Mottram, J.C. The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Mol. Biochem. Parasitol. 2001, 113, 189–198.
55. Späth, G.F.; Clos, J. Joining forces: First application of a rapamycin-induced dimerizable Cre system for conditional null mutant analysis in Leishmania. Mol. Microbiol. 2016, 100, 923–927.
56. Duncan, S.M.; Myburgh, E.; Philipon, C.; Brown, E.; Meissner, M.; Brewer, J.; Mottram, J.C. Conditional gene deletion with DiCre demonstrates an essential role for CRK3 in Leishmania mexicana cell cycle regulation. Mol. Microbiol. 2016, 100, 931–944.
57. Ali, N.O.; Ibrahim, M.E.; Grant, K.M.; Mottram, J.C. Leishmania mexicana: Expression; characterization and activity assessment of E. coli-expressed recombinant CRK3. Eur. Rev. Med. Pharmacol. Sci. 2012, 16, 1338–1345.
58. Gomes, F.C.; Ali, N.O.; Brown, E.; Walker, R.G.; Grant, K.M.; Mottram, J.C. Recombinant Leishmania mexicana CRK3:CYCA has protein kinase activity in the absence of phosphorylation on the T-loop residue Thr178. Mol. Biochem. Parasitol. 2010, 171, 89–96.
59. Banerjee, S.; Sen, A.; Das, P.; Saha, P. Leishmania donovani cyclin 1 (LdCyc1) forms a complex with cell cycle kinase subunit CRK3 (LdCRK3) and is possibly involved in S-phase-related activities. FEMS Microbiol. Lett. 2006, 256, 75–82.
60. Wang, Y.; Dimitrov, K.; Garrity, L.K.; Sazer, S.; Beverley, S.M. Stage-specific activity of the Leishmania major CRK3 kinase and functional rescue of a Schizosaccharomyces pombe cdc2 mutant. Mol. Biochem. Parasitol. 1998, 96, 139–150.
61. Řezníčková, E.; Popa, A.; Gucký, T.; Zatloukal, M.; Havlíček, L.; Bazgier, V.; Berka, K.; Jorda, R.; Popa, I.; Nasereddin, A.; et al. 2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro. Bioorg. Med. Chem. Lett. 2015, 25, 2298–2301.
62. Cleghorn, L.A.; Woodland, A.; Collie, I.T.; Torrie, L.S.; Norcross, N.; Luksch, T.; Mpamhanga, C.; Walker, R.G.; Mottram, J.C.; Brenk, R.; et al. Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3. ChemMedChem 2011, 6, 2214–2224.
63. Walker, R.G.; Thomson, G.; Malone, K.; Nowicki, M.W.; Brown, E.; Blake, D.G.; Turner, N.J.; Walkinshaw, M.D.; Grant, K.M.; Mottram, J.C. High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase. PLoS Negl. Trop. Dis. 2011, 5, e1033.
64. Maity, A.K.; Goswami, A.; Saha, P. Identification of substrates of an S-phase cell cycle kinase from Leishmania donovani. FEBS Lett. 2011, 585, 2635–2639.
65. Jorda, R.; Sacerdoti-Sierra, N.; Voller, J.; Havlíček, L.; Kráčalíková, K.; Nowicki, M.W.; Nasereddin, A.; Kryštof, V.; Strnad, M.; Walkinshaw, M.D.; et al. Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines. Bioorg. Med. Chem. Lett. 2011, 21, 4233–4237.
66. Wyllie, S.; Thomas, M.; Patterson, S.; Crouch, S.; De Rycker, M.; Lowe, R.; Gresham, S.; Urbaniak, M.D.; Otto, T.D.; Stojanovski, L.; et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature 2018, 560, 192–197.
67. Mottram, J.C.; McCready, B.P.; Brown, K.G.; Grant, K.M. Gene disruptions indicate an essential function for the LmmCRK1 cdc2-related kinase of Leishmania mexicana. Mol. Microbiol. 1996, 22, 573–583.
68. Phukan, S.; Babu, V.S.; Kannoji, A.; Hariharan, R.; Balaji, V.N. GSK3beta: Role in therapeutic landscape and development of modulators. Br. J. Pharmacol. 2010, 160, 1–19.
69. Ojo, K.K.; Gillespie, J.R.; Riechers, A.J.; Napuli, A.J.; Verlinde, C.L.; Buckner, F.S.; Gelb, M.H.; Domostoj, M.M.; Wells, S.J.; Scheer, A.; et al. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob. Agents Chemother. 2008, 52, 3710–3717.
70. Ojo, K.K.; Arakaki, T.L.; Napuli, A.J.; Inampudi, K.K.; Keyloun, K.R.; Zhang, L.; Hol, W.G.; Verlinde, C.L.; Merritt, E.A.; Van Voorhis, W.C. Structure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3. Mol. Biochem. Parasitol. 2011, 176, 98–108.
71. Knockaert, M.; Wieking, K.; Schmitt, S.; Leost, M.; Grant, K.M.; Mottram, J.C.; Kunick, C.; Meijer, L. Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor. J. Biol. Chem. 2002, 277, 25493–25501.
72. Martínez de Iturrate, P.; Sebastián-Pérez, V.; Nácher-Vázquez, M.; Tremper, C.S.; Smirlis, D.; Martín, J.; Martínez, A.; Campillo, N.E.; Rivas, L.; Gil, C. Towards discovery of new leishmanicidal scaffolds able to inhibit. J. Enzyme Inhib. Med. Chem. 2020, 35, 199–210.
73. Leost, M.; Schultz, C.; Link, A.; Wu, Y.Z.; Biernat, J.; Mandelkow, E.M.; Bibb, J.A.; Snyder, G.L.; Greengard, P.; Zaharevitz, D.W.; et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur. J. Biochem. 2000, 267, 5983–5994.
74. Coghlan, M.P.; Culbert, A.A.; Cross, D.A.; Corcoran, S.L.; Yates, J.W.; Pearce, N.J.; Rausch, O.L.; Murphy, G.J.; Carter, P.S.; Roxbee Cox, L.; et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 2000, 7, 793–803.
75. Smith, D.G.; Buffet, M.; Fenwick, A.E.; Haigh, D.; Ife, R.J.; Saunders, M.; Slingsby, B.P.; Stacey, R.; Ward, R.W. 3-Anilino-4-arylmaleimides: Potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 2001, 11, 635–639.
76. Ryves, W.J.; Harwood, A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 2001, 280, 720–725.
77. Henriksen, E.J.; Kinnick, T.R.; Teachey, M.K.; O’Keefe, M.P.; Ring, D.; Johnson, K.W.; Harrison, S.D. Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E892–E900.
78. Kaidanovich-Beilin, O.; Eldar-Finkelman, H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: Molecular characterization in liver and muscle. J. Pharmacol. Exp. Ther. 2006, 316, 17–24.
79. Kannan, N.; Neuwald, A.F. Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha. Protein. Sci. 2004, 13, 2059–2077.
80. Becker, W.; Joost, H.G. Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog. Nucleic Acid. Res. Mol. Biol. 1999, 62, 1–17.
81. Aranda, S.; Laguna, A.; de la Luna, S. DYRK family of protein kinases: Evolutionary relationships, biochemical properties, and functional roles. FASEB J. 2011, 25, 449–462.
82. Tejedor, F.; Zhu, X.R.; Kaltenbach, E.; Ackermann, A.; Baumann, A.; Canal, I.; Heisenberg, M.; Fischbach, K.F.; Pongs, O. minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron 1995, 14, 287–301.
83. Garrett, S.; Broach, J. Loss of Ras activity in Saccharomyces cerevisiae is suppressed by disruptions of a new kinase gene, YAKI, whose product may act downstream of the cAMP-dependent protein kinase. Genes Dev. 1989, 3, 1336–1348.
84. Garrett, S.; Menold, M.M.; Broach, J.R. The Saccharomyces cerevisiae YAK1 gene encodes a protein kinase that is induced by arrest early in the cell cycle. Mol. Cell. Biol. 1991, 11, 4045–4052.
85. Schmitz, M.L.; Rodriguez-Gil, A.; Hornung, J. Integration of stress signals by homeodomain interacting protein kinases. Biol. Chem. 2014, 395, 375–386.
86. Huang, Y.; Deng, T.; Winston, B.W. Characterization of hPRP4 kinase activation: Potential role in signaling. Biochem. Biophys. Res. Commun. 2000, 271, 456–463.
87. Møller, R.S.; Kübart, S.; Hoeltzenbein, M.; Heye, B.; Vogel, I.; Hansen, C.P.; Menzel, C.; Ullmann, R.; Tommerup, N.; Ropers, H.H.; et al. Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. Am. J. Hum. Genet. 2008, 82, 1165–1170.
88. Park, J.; Song, W.J.; Chung, K.C. Function and regulation of Dyrk1A: Towards understanding Down syndrome. Cell Mol. Life Sci. 2009, 66, 3235–3240.
89. Kuhn, C.; Frank, D.; Will, R.; Jaschinski, C.; Frauen, R.; Katus, H.A.; Frey, N. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy. J. Biol. Chem. 2009, 284, 17320–17327.
90. Lee, Y.; Ha, J.; Kim, H.J.; Kim, Y.S.; Chang, E.J.; Song, W.J.; Kim, H.H. Negative feedback Inhibition of NFATc1 by DYRK1A regulates bone homeostasis. J. Biol. Chem. 2009, 284, 33343–33351.
91. Ryoo, S.R.; Jeong, H.K.; Radnaabazar, C.; Yoo, J.J.; Cho, H.J.; Lee, H.W.; Kim, I.S.; Cheon, Y.H.; Ahn, Y.S.; Chung, S.H.; et al. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease. J. Biol. Chem. 2007, 282, 34850–34857.
92. Friedman, E. Mirk/Dyrk1B in cancer. J. Cell Biochem. 2007, 102, 274–279.
93. Rocha, V.P.C.; Dacher, M.; Young, S.A.; Kolokousi, F.; Efstathiou, A.; Späth, G.F.; Soares, M.B.P.; Smirlis, D. Leishmania dual-specificity tyrosine-regulated kinase 1 (DYRK1) is required for sustaining Leishmania stationary phase phenotype. Mol. Microbiol. 2020, 113, 983–1002.
94. Loaëc, N.; Attanasio, E.; Villiers, B.; Durieu, E.; Tahtouh, T.; Cam, M.; Davis, R.A.; Alencar, A.; Roué, M.; Bourguet-Kondracki, M.L.; et al. Marine-Derived 2-Aminoimidazolone Alkaloids. Leucettamine B-Related Polyandrocarpamines Inhibit Mammalian and Protozoan DYRK & CLK Kinases. Mar. Drugs 2017, 15, 316.
95. Murakami, N.; Bolton, D.; Hwang, Y.W. Dyrk1A binds to multiple endocytic proteins required for formation of clathrin-coated vesicles. Biochemistry 2009, 48, 9297–9305.
96. Murakami, N.; Bolton, D.C.; Kida, E.; Xie, W.; Hwang, Y.W. Phosphorylation by Dyrk1A of clathrin coated vesicle-associated proteins: Identification of the substrate proteins and the effects of phosphorylation. PLoS ONE 2012, 7, e34845.
97. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B.E.; Karandikar, M.; Berman, K.; Cobb, M.H. Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr. Rev. 2001, 22, 153–183.
98. Yu, J.; Sun, X.; Goie, J.Y.G.; Zhang, Y. Regulation of Host Immune Responses against Influenza A Virus Infection by Mitogen-Activated Protein Kinases (MAPKs). Microorganisms 2020, 8, 1067.
99. Miyata, Y.; Akashi, M.; Nishida, E. Molecular cloning and characterization of a novel member of the MAP kinase superfamily. Genes Cells 1999, 4, 299–309.
100. Ferrell, J.E.; Bhatt, R.R. Mechanistic studies of the dual phosphorylation of mitogen-activated protein kinase. J. Biol. Chem. 1997, 272, 19008–19016.
101. Naula, C.; Parsons, M.; Mottram, J.C. Protein kinases as drug targets in trypanosomes and Leishmania. Biochim. Biophys. Acta 2005, 1754, 151–159.
102. Wiese, M. A mitogen-activated protein (MAP) kinase homologue of Leishmania mexicana is essential for parasite survival in the infected host. EMBO J. 1998, 17, 2619–2628.
103. Kaur, P.; Garg, M.; Hombach-Barrigah, A.; Clos, J.; Goyal, N. MAPK1 of Leishmania donovani interacts and phosphorylates HSP70 and HSP90 subunits of foldosome complex. Sci. Rep. 2017, 7, 10202.
104. Hombach-Barrigah, A.; Bartsch, K.; Smirlis, D.; Rosenqvist, H.; MacDonald, A.; Dingli, F.; Loew, D.; Späth, G.F.; Rachidi, N.; Wiese, M.; et al. Leishmania donovani 90 kD Heat Shock Protein—Impact of Phosphosites on Parasite Fitness, Infectivity and Casein Kinase Affinity. Sci. Rep. 2019, 9, 5074.
105. Morales, M.A.; Watanabe, R.; Dacher, M.; Chafey, P.; Osorio y Fortéa, J.; Scott, D.A.; Beverley, S.M.; Ommen, G.; Clos, J.; Hem, S.; et al. Phosphoproteome dynamics reveal heat-shock protein complexes specific to the Leishmania donovani infectious stage. Proc. Natl. Acad. Sci. USA 2010, 107, 8381–8386.
106. Garg, M.; Goyal, N. MAPK1 of Leishmania donovani modulates antimony susceptibility by downregulating P-glycoprotein efflux pumps. Antimicrob. Agents Chemother. 2015, 59, 3853–3863.
107. Mandal, G.; Sharma, M.; Kruse, M.; Sander-Juelch, C.; Munro, L.A.; Wang, Y.; Vilg, J.V.; Tamás, M.J.; Bhattacharjee, H.; Wiese, M.; et al. Modulation of Leishmania major aquaglyceroporin activity by a mitogen-activated protein kinase. Mol. Microbiol. 2012, 85, 1204–1218.
108. Goldman-Pinkovich, A.; Balno, C.; Strasser, R.; Zeituni-Molad, M.; Bendelak, K.; Rentsch, D.; Ephros, M.; Wiese, M.; Jardim, A.; Myler, P.J.; et al. An Arginine Deprivation Response Pathway Is Induced in Leishmania during Macrophage Invasion. PLoS Pathog. 2016, 12, e1005494.
109. Erdmann, M.; Scholz, A.; Melzer, I.M.; Schmetz, C.; Wiese, M. Interacting protein kinases involved in the regulation of flagellar length. Mol. Biol. Cell 2006, 17, 2035–2045.
110. Bengs, F.; Scholz, A.; Kuhn, D.; Wiese, M. LmxMPK9, a mitogen-activated protein kinase homologue affects flagellar length in Leishmania mexicana. Mol. Microbiol. 2005, 55, 1606–1615.
111. Wiese, M.; Kuhn, D.; Grünfelder, C.G. Protein kinase involved in flagellar-length control. Eukaryot. Cell 2003, 2, 769–777.
112. Raj, S.; Saha, G.; Sasidharan, S.; Dubey, V.K.; Saudagar, P. Biochemical characterization and chemical validation of Leishmania MAP Kinase-3 as a potential drug target. Sci. Rep. 2019, 9, 16209.
113. Wernimont, A.K.; Walker, J.R.; Hutchinson, A.; Loppnau, P.; Edwards, A.M.; Arrowsmith, C.H.; Bountra, C.; Hui, R.; Mangos, M. Crystal Structure of MPK3 from Leishmania Donovani, LdBPK_100540 in the Presence of NVP-BBT594. Available online: (accessed on 15 February 2021).
114. Herrera-Acevedo, C.; Dos Santos Maia, M.; Cavalcanti, É.; Coy-Barrera, E.; Scotti, L.; Scotti, M.T. Selection of antileishmanial sesquiterpene lactones from SistematX database using a combined ligand-/structure-based virtual screening approach. Mol. Divers. 2020.
115. Morales, M.A.; Renaud, O.; Faigle, W.; Shorte, S.L.; Späth, G.F. Over-expression of Leishmania major MAP kinases reveals stage-specific induction of phosphotransferase activity. Int. J. Parasitol. 2007, 37, 1187–1199.
116. Morales, M.A.; Pescher, P.; Späth, G.F. Leishmania major MPK7 protein kinase activity inhibits intracellular growth of the pathogenic amastigote stage. Eukaryot. Cell 2010, 9, 22–30.
117. Wang, Q.; Melzer, I.M.; Kruse, M.; Sander-Juelch, C.; Wiese, M. LmxMPK4, a mitogen-activated protein (MAP) kinase homologue essential for promastigotes and amastigotes of Leishmania mexicana. Kinetoplastid Biol. Dis. 2005, 4, 6.
118. Dacher, M.; Morales, M.A.; Pescher, P.; Leclercq, O.; Rachidi, N.; Prina, E.; Cayla, M.; Descoteaux, A.; Späth, G.F. Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses. Mol. Microbiol. 2014, 93, 146–166.
119. John von Freyend, S.; Rosenqvist, H.; Fink, A.; Melzer, I.M.; Clos, J.; Jensen, O.N.; Wiese, M. LmxMPK4, an essential mitogen-activated protein kinase of Leishmania mexicana is phosphorylated and activated by the STE7-like protein kinase LmxMKK5. Int. J. Parasitol. 2010, 40, 969–978.
120. Raj, S.; Sasidharan, S.; Dubey, V.K.; Saudagar, P. Identification of lead molecules against potential drug target protein MAPK4 from L. donovani: An in-silico approach using docking, molecular dynamics and binding free energy calculation. PLoS ONE 2019, 14, e0221331.
121. Saravanan, P.; Venkatesan, S.K.; Mohan, C.G.; Patra, S.; Dubey, V.K. Mitogen-activated protein kinase 4 of Leishmania parasite as a therapeutic target. Eur. J. Med. Chem. 2010, 45, 5662–5670.
122. Wanders, P. In Vitro and In Vivo Characterization of a L. mexicana Lmx MPK5 Null Mutant. Master’s Thesis, Technische Hochschule Hannover, Hannover, Germany, 2004.
123. Cayla, M.; Rachidi, N.; Leclercq, O.; Schmidt-Arras, D.; Rosenqvist, H.; Wiese, M.; Späth, G.F. Transgenic analysis of the Leishmania MAP kinase MPK10 reveals an auto-inhibitory mechanism crucial for stage-regulated activity and parasite viability. PLoS Pathog. 2014, 10, e1004347.
124. Horjales, S.; Schmidt-Arras, D.; Limardo, R.R.; Leclercq, O.; Obal, G.; Prina, E.; Turjanski, A.G.; Späth, G.F.; Buschiazzo, A. The crystal structure of the MAP kinase LmaMPK10 from Leishmania major reveals parasite-specific features and regulatory mechanisms. Structure 2012, 20, 1649–1660.
125. Cozza, G.; Pinna, L.A. Casein kinases as potential therapeutic targets. Expert Opin. Ther. Targets 2016, 20, 319–340.
126. Knippschild, U.; Gocht, A.; Wolff, S.; Huber, N.; Löhler, J.; Stöter, M. The casein kinase 1 family: Participation in multiple cellular processes in eukaryotes. Cell Signal. 2005, 17, 675–689.
127. Eide, E.J.; Virshup, D.M. Casein kinase I: Another cog in the circadian clockworks. Chronobiol. Int. 2001, 18, 389–398.
128. Price, M.A. CKI, there’s more than one: Casein kinase I family members in Wnt and Hedgehog signaling. Genes Dev. 2006, 20, 399–410.
129. Aoki, K.; Yoshida, K. Biological Consequences of Priming Phosphorylation in Cancer Development. Protein Phosphorylation 2017.
130. Flotow, H.; Graves, P.R.; Wang, A.Q.; Fiol, C.J.; Roeske, R.W.; Roach, P.J. Phosphate groups as substrate determinants for casein kinase I action. J. Biol. Chem. 1990, 265, 14264–14269.
131. Götz, C.; Montenarh, M. Protein kinase CK2 in development and differentiation. Biomed. Rep. 2017, 6, 127–133.
132. Rachidi, N.; Taly, J.F.; Durieu, E.; Leclercq, O.; Aulner, N.; Prina, E.; Pescher, P.; Notredame, C.; Meijer, L.; Späth, G.F. Pharmacological assessment defines Leishmania donovani casein kinase 1 as a drug target and reveals important functions in parasite viability and intracellular infection. Antimicrob. Agents Chemother. 2014, 58, 1501–1515.
133. Sacerdoti-Sierra, N.; Jaffe, C.L. Release of ecto-protein kinases by the protozoan parasite Leishmania major. J. Biol. Chem. 1997, 272, 30760–30765.
134. Silverman, J.M.; Chan, S.K.; Robinson, D.P.; Dwyer, D.M.; Nandan, D.; Foster, L.J.; Reiner, N.E. Proteomic analysis of the secretome of Leishmania donovani. Genome Biol. 2008, 9, R35.
135. Silverman, J.M.; Clos, J.; de’Oliveira, C.C.; Shirvani, O.; Fang, Y.; Wang, C.; Foster, L.J.; Reiner, N.E. An exosome-based secretion pathway is responsible for protein export from Leishmania and communication with macrophages. J. Cell Sci. 2010, 123, 842–852.
136. Liu, J.; Carvalho, L.P.; Bhattacharya, S.; Carbone, C.J.; Kumar, K.G.; Leu, N.A.; Yau, P.M.; Donald, R.G.; Weiss, M.J.; Baker, D.P.; et al. Mammalian casein kinase 1alpha and its leishmanial ortholog regulate stability of IFNAR1 and type I interferon signaling. Mol. Cell. Biol. 2009, 29, 6401–6412.
137. Allocco, J.J.; Donald, R.; Zhong, T.; Lee, A.; Tang, Y.S.; Hendrickson, R.C.; Liberator, P.; Nare, B. Inhibitors of casein kinase 1 block the growth of Leishmania major promastigotes in vitro. Int. J. Parasitol. 2006, 36, 1249–1259.
138. Durieu, E.; Prina, E.; Leclercq, O.; Oumata, N.; Gaboriaud-Kolar, N.; Vougogiannopoulou, K.; Aulner, N.; Defontaine, A.; No, J.H.; Ruchaud, S.; et al. From Drug Screening to Target Deconvolution: A Target-Based Drug Discovery Pipeline Using Leishmania Casein Kinase 1 Isoform 2 To Identify Compounds with Antileishmanial Activity. Antimicrob. Agents Chemother. 2016, 60, 2822–2833.
139. Dan-Goor, M.; Nasereddin, A.; Jaber, H.; Jaffe, C.L. Identification of a secreted casein kinase 1 in Leishmania donovani: Effect of protein over expression on parasite growth and virulence. PLoS ONE 2013, 8, e79287.
140. Martel, D.; Beneke, T.; Gluenz, E.; Späth, G.F.; Rachidi, N. Characterisation of Casein Kinase 1.1 in Leishmania donovani Using the CRISPR Cas9 Toolkit. Biomed. Res. Int 2017, 2017, 4635605.
141. Dutra, P.M.; Vieira, D.P.; Meyer-Fernandes, J.R.; Silva-Neto, M.A.; Lopes, A.H. Stimulation of Leishmania tropica protein kinase CK2 activities by platelet-activating factor (PAF). Acta Trop. 2009, 111, 247–254.
142. Becker, S.; Jaffe, C.L. Effect of protein kinase inhibitors on the growth, morphology, and infectivity of Leishmania promastigotes. Parasitol. Res. 1997, 83, 273–280.
143. Vieira, L.L.; Sacerdoti-Sierra, N.; Jaffe, C.L. Effect of pH and temperature on protein kinase release by Leishmania donovani. Int J. Parasitol. 2002, 32, 1085–1093.
144. Zylbersztejn, A.M.; de Morais, C.G.; Lima, A.K.; Souza, J.E.; Lopes, A.H.; Da-Silva, S.A.; Silva-Neto, M.A.; Dutra, P.M. CK2 Secreted by Leishmania braziliensis Mediates Macrophage Association Invasion: A Comparative Study between Virulent and Avirulent Promastigotes. Biomed. Res. Int. 2015, 2015, 167323.
145. Silva-Neto, M.A.; Carneiro, A.B.; Vieira, D.P.; Mesquita, R.D.; Lopes, A.H. Platelet-activating factor (PAF) activates casein kinase 2 in the protozoan parasite Herpetomonas muscarum muscarum. Biochem. Biophys. Res. Commun. 2002, 293, 1358–1363.
146. Crane, R.; Gadea, B.; Littlepage, L.; Wu, H.; Ruderman, J.V. Aurora A, meiosis and mitosis. Biol. Cell 2004, 96, 215–229.
147. Tu, X.; Kumar, P.; Li, Z.; Wang, C.C. An aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei. J. Biol. Chem. 2006, 281, 9677–9687.
148. Siman-Tov, M.M.; Ivens, A.C.; Jaffe, C.L. Identification and cloning of Lmairk, a member of the Aurora/Ipl1p protein kinase family, from the human protozoan parasite Leishmania. Biochim. Biophys. Acta 2001, 1519, 241–245.
149. Reininger, L.; Wilkes, J.M.; Bourgade, H.; Miranda-Saavedra, D.; Doerig, C. An essential Aurora-related kinase transiently associates with spindle pole bodies during Plasmodium falciparum erythrocytic schizogony. Mol. Microbiol. 2011, 79, 205–221.
150. Chhajer, R.; Bhattacharyya, A.; Didwania, N.; Shadab, M.; Das, N.; Palit, P.; Vaidya, T.; Ali, N. Leishmania donovani Aurora kinase: A promising therapeutic target against visceral leishmaniasis. Biochim. Biophys. Acta 2016, 1860, 1973–1988.
151. Patel, G.; Roncal, N.E.; Lee, P.J.; Leed, S.E.; Erath, J.; Rodriguez, A.; Sciotti, R.J.; Pollastri, M.P. Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery. Medchemcomm 2014, 5, 655–658.
152. Varela-M, R.E.; Ochoa, R.; Muskus, C.E.; Muro, A.; Mollinedo, F. Identification of a RAC/AKT-like gene in Leishmania parasites as a putative therapeutic target in leishmaniasis. Parasit. Vectors 2017, 10, 458.
153. Tirado-Duarte, D.; Marín-Villa, M.; Ochoa, R.; Blandón-Fuentes, G.; Soares, M.J.; Robledo, S.M.; Varela-Miranda, R.E. The Akt-like kinase of Leishmania panamensis: As a new molecular target for drug discovery. Acta Trop. 2018, 177, 171–178.
154. Nandan, D.; Zhang, N.; Yu, Y.; Schwartz, B.; Chen, S.; Kima, P.E.; Reiner, N.E. Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania. PLoS ONE 2018, 13, e0206920.
155. Jha, M.K.; Rao, S.J.; Sarode, A.Y.; Saha, B.; Kar, A.; Pal, J.K. A Leishmania donovani dominant-negative mutant for eIF2α kinase LdeK1 elicits host-protective immune response. Parasite Immunol. 2020, 42, e12678.
156. Abhishek, K.; Sardar, A.H.; Das, S.; Kumar, A.; Ghosh, A.K.; Singh, R.; Saini, S.; Mandal, A.; Verma, S.; Purkait, B.; et al. Phosphorylation of Translation Initiation Factor 2-Alpha in Leishmania donovani under Stress Is Necessary for Parasite Survival. Mol. Cell. Biol. 2017, 37.
157. Vacas, A.; Fernández-Rubio, C.; Algarabel, M.; Peña-Guerrero, J.; Larrea, E.; Rocha Formiga, F.; García-Sosa, A.T.; Nguewa, P.A. The Novel Serine/Threonine Protein Kinase LmjF.22.0810 from. Biomolecules 2019, 9, 723.
158. Srivastava, A.; Garg, S.; Jain, R.; Ayana, R.; Kaushik, H.; Garg, L.; Pati, S.; Singh, S. Identification and functional characterization of a bacterial homologue of Zeta toxin in Leishmania donovani. FEBS Lett. 2019, 593, 1223–1235.